Bactiguard Holding AB
STO:BACTI B
Intrinsic Value
Bactiguard Holding AB is a medical device company, which engages in the development and supply of infection protection solutions. [ Read More ]
The intrinsic value of one
BACTI B
stock under the Base Case scenario is
26.38
SEK.
Compared to the current market price of 71.8 SEK,
Bactiguard Holding AB
is
Overvalued by 63%.
BACTI B's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
BACTI B or that its price is influenced by factors unrelated to fundamentals.
Bactiguard Holding AB's market capitalization is 2.5B SEK.
BACTI B stock price is 71.8 SEK.
BACTI B stock (26.38 SEK) is 63% less than its price (71.8 SEK).
BACTI B stock (36.56 SEK) is 49% less than its price (71.8 SEK). Open Relative Valuation
BACTI B has downside potential of 35% compared to the average analyst price target.
Open Wall St Estimates
BACTI B's ROE (Return on Equity) has decreased in the last 3 years from -10% to -12%, and is approaching profitability.
BACTI B's Revenue is forecast to grow at a rate of 2% per year over the next 3 years.
BACTI B has negative Free Cash Flow for the last twelve months.
BACTI B's ROIC (Return on Invested Capital) has decreased in the last 3 years from -4% to -9%, and is approaching profitability.
BACTI B has positive Net Debt. This means that the company has more debt (230m SEK) than cash and short-term investments (187m SEK).
BACTI B's Revenue has grown by an exceptional 35% over the past 12 months.
BACTI B's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -9%.
BACTI B's ROE (Return on Equity) for the past 12 months is negative and is equal to -12%.
BACTI B has negative Operating Income for the last twelve months.
BACTI B has negative Net Income for the last twelve months.
BACTI B has positive Gross Profit for the last twelve months.
BACTI B has negative three-year average ROIC (Return on Invested Capital): -5%. The company is not efficient at using invested capital to generate operating income.
BACTI B's long-term assets (786m SEK) exceed its long-term liabilties (312m SEK).
BACTI B's D/E (Debt to Equity) is very low and is equal to 0.49.
BACTI B has negative three-year average ROE (Return on Equity): -9%. The company is not efficient at transforming stockholders' equity into net income.
BACTI B's short-term assets (291m SEK) exceed its short-term liabilties (82m SEK).
BACTI B's Altman Z-Score is very high and is equal to 4.28.
Valuation Backtest
Bactiguard Holding AB
Run backtest to discover the historical profit from buying and selling
BACTI B
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bactiguard Holding AB
Balance Sheet Decomposition
Bactiguard Holding AB
| Current Assets | 291.3m |
| Cash & Short-Term Investments | 186.6m |
| Receivables | 48.4m |
| Other Current Assets | 56.3m |
| Non-Current Assets | 494.2m |
| PP&E | 102.8m |
| Intangibles | 388.2m |
| Other Non-Current Assets | 3.2m |
| Current Liabilities | 82.4m |
| Accounts Payable | 30.5m |
| Accrued Liabilities | 34.1m |
| Other Current Liabilities | 17.9m |
| Non-Current Liabilities | 229.8m |
| Long-Term Debt | 229.8m |
Earnings Waterfall
Bactiguard Holding AB
|
Revenue
|
259.5m
SEK
|
|
Cost of Revenue
|
-132.1m
SEK
|
|
Gross Profit
|
127.4m
SEK
|
|
Operating Expenses
|
-185.2m
SEK
|
|
Operating Income
|
-57.8m
SEK
|
|
Other Expenses
|
-693k
SEK
|
|
Net Income
|
-58.5m
SEK
|
Free Cash Flow Analysis
Bactiguard Holding AB
BACTI B Profitability Score
Profitability Due Diligence
Bactiguard Holding AB's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Bactiguard Holding AB's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
BACTI B Solvency Score
Solvency Due Diligence
Bactiguard Holding AB's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Bactiguard Holding AB's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BACTI B Price Targets Summary
Bactiguard Holding AB
According to Wall Street analysts, the average 1-year price target for
BACTI B
is 47 SEK
.
Shareholder Return
BACTI B Price
Bactiguard Holding AB
| Average Annual Return | 44.54% |
| Standard Deviation of Annual Returns | 65.54% |
| Max Drawdown | -74% |
| Market Capitalization | 2.5B SEK |
| Shares Outstanding | 35 043 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Bactiguard Holding AB
Country
Industry
Market Cap
Dividend Yield
Description
Bactiguard Holding AB is a medical device company, which engages in the development and supply of infection protection solutions. The company is headquartered in Stockholm, Stockholm and currently employs 188 full-time employees. The company went IPO on 2014-06-19. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. The company consists of the noble metals: gold, palladium and silver, which reduces the adhesion of bacteria to the coated surfaces. Its product portfolio includes: BIP Foley Catherer, made from medical grade latex, and BIP Foley Catheter - Silicone, used for drainage and irrigation of the bladder; BIP Endotracheal Tube, for general anesthesia, intensive care, and emergency medicine for airway management and mechanical ventilation; and BIP Central Venous Catherer, made of polyurethane and used to administer drugs and intravenous solutions, monitor pressure and blood sampling. The firm is also present in Portugal, via a distribution agreement with Socime Medical Ltd, and Zambia.
Contact
IPO
Employees
Officers
The intrinsic value of one
BACTI B
stock under the Base Case scenario is
26.38
SEK.
Compared to the current market price of 71.8 SEK,
Bactiguard Holding AB
is
Overvalued by 63%.
You don't have any saved screeners yet
